DSG3 and myasthenia gravis: Preclinical studies on MuSK-CAART for myasthenia gravis treatment [27] and desmoglein 3 (DSG3)-CAART for mucosal pemphigus vulgaris [26] have shown that both CAARTs retained efficient levels of cytolysis activity in the presence of soluble antibodies.